Navigation Links
Most Leukemia Patients Recover From 'Chemo Brain' After Transplant: Study
Date:5/6/2011

FRIDAY, May 6 (HealthDay News) -- A decline in memory and fine-motor skills is common among patients who undergo a bone marrow or stem cell transplant to treat leukemia or lymphoma, but most patients return to normal within five years, according to a new study.

Previous research has shown that the chemotherapy drugs these patients take before transplantation and medicines they take to prevent rejection of the transplanted cells can affect memory and motor skills. This study looked at how long it takes them to recover from those problems, often referred to as "chemo brain."

The study included 92 patients with chronic myeloid leukemia, acute leukemia, lymphoma or myelodysplastic syndrome, in which the bone marrow does not function normally. The patients had received an allogeneic (cells donated by another person) bone marrow or stem cell transplant.

After treatment, the patients' memory and motor skills were assessed. Most patients showed substantial improvement in neurocognitive function between one and five years after their transplant.

But deficits, described as mostly mild, persisted for five years in nearly 42 percent of the patients, a finding that surprised the researchers at the Fred Hutchinson Cancer Research Center in Seattle.

"We really thought the rates would be lower," study leader Karen Syrjala, director of Biobehavioral Sciences, said in a Hutchinson news release. "We were thrilled to see that people recovered substantially, but we also were surprised that so many people did continue to have measurable deficits in some areas even after five years."

Further research is needed to identify the reasons for these persistent deficits, she added.

The study was published May 2 online in the Journal of Clinical Oncology.

More information

The U.S. National Heart, Lung, and Blood Institute has more about bone marrow and stem cell transplant.

-- Robert Preidt

SOURCE: Fred Hutchinson Cancer Research Center, news release, May 3, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Agent selectively targets malignant B cells in chronic leukemia, study shows
2. Possible new approach to treating deadly leukemia in babies
3. New drug shows potential for treatment-resistant leukemia
4. ASH partners with AMEH and National Cancer Institute to improve diagnosis of leukemia in Mexico
5. Tracking down the origin of leukemia relapse
6. New approach to leukemia chemotherapy -- is a cure in sight?
7. UCSF researchers identify promising new treatment for childhood leukemia
8. Study reveals no impact of age on outcome in chronic myeloid leukemia patients treated with imatinib
9. Leukemia Patients Taking Gleevec Achieve Normal Death Rate
10. Less Is More With Acute Myeloid Leukemia Drug
11. When leukemia returns, gene that mediates response to key drug often mutated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... ... personal financial planning to families and business owners in North Central West Virginia, ... help provide services to differently abled residents in the region. , The Stepping ...
(Date:6/22/2017)... ... 2017 , ... Plastic Surgery Associates is proud to report that founding surgeon, ... research and information firm, Castle Connolly, releases their list of the most notable and ... 3rd time that Dr. Canales has been recognized by Castle Connolly. , ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... grant from the American Heart Association (AHA) to launch a Rheumatic Heart Disease ... the prevention and diagnosis of rheumatic heart disease (RHD) in high-risk, financially disadvantaged ...
(Date:6/22/2017)... ... June 22, 2017 , ... Vighter, a premier provider ... certification for ANSI/ASIS PSC.1-2012. The company’s work in countries throughout Southwest Asia, South ... law has been degraded. The PSC.1 standard was created to protect fundamental freedoms ...
(Date:6/20/2017)... ... June 20, 2017 , ... TwelveStone Health Partners, a premier ... private equity firm, has invested $3.35 million in the company. , “We ... Capital offers the smart money, speed to market and accountability we had been ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... 2017   Responding to Heath Ledger,s father,s ... of singer Chris Cornell in May, the mental ... a free online psychiatric drug side effects ... about psychotropic drug risks. The father of ... an accidental overdose, has called for tighter rules on prescription ...
(Date:6/7/2017)... June 7, 2017  Novavax, Inc., (Nasdaq: NVAX ... Phase 2 trials of its RSV F protein recombinant nanoparticle ... age have been published in the journal Vaccine ... shared in prior scientific conferences). The Company previously announced ... Novavax is developing the RSV F Vaccine with the goal ...
(Date:6/5/2017)... June 5, 2017 Kohll,s Pharmacy & Homecare is the ... the United States . The Raizer is a simple ... person up to an almost-standing position within a ... by one assistant and does not require any ... that a child can operate it, and lightweight ...
Breaking Medicine Technology: